Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (231)	10/21/2009 4:54:15 PM
From: John McCarthy	Respond to of 421

Hi Arthur Some guys on the Yahoo board are ALSO saying they got a phone call. I feel left out -g- regards John

To: Arthur Radley who wrote (231)	11/1/2009 10:12:45 PM
From: John McCarthy	Read Replies (1) \| Respond to of 421

Alimera Sciences Inc., an Atlanta-based ophthalmic pharmaceutical company, has filed for an $80 million IPO. This comes less than two months after Alimera withdrew registration for a $75 million IPO due to “current public market conditions.” It had planned to trade on the Nasdaq under ticker symbol ALIM, with Credit Suisse and Citi serving as co-lead underwriters. Alimera has raised just over $71 million in VC funding since 2004, from firms like Scale Venture Partners (18.44% pre-IPO stake), Domain Associates (18.44%), Intersouth Partners (18.44%), Polaris Venture Partners (18.44%) and Venrock Associates (14.93%). It also received a total of $16.7 million from the sale of two OTC allergy products and a lubricating eye from to Bausch & Lomb. www.alimerasciences.com pehub.com